Biological matter

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021

The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Biocomposites presents STIMULAN® data at the MSIS 31st Annual Open Scientific Meeting 2021

Retrieved on: 
Wednesday, August 4, 2021

KEELE, England, Aug. 4, 2021 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the Musculoskeletal Infection Society's 31st Annual Open Scientific Meeting, which is being held in Fort Lauderdale 6-7 August 2021. The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.

Key Points: 
  • The company will be sharing research findings relating to the antimicrobial effectiveness of STIMULAN mixed with antibiotics against multispecies biofilm.
  • It also showed that STIMULAN bead distribution plays an important role in biofilm eradication and reduction of challenging resistant variant colonies.
  • Details of the posters are listed below with links to the 31st Annual Open Scientific Meeting website.
  • Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world.

Kane Biotech Announces Cancellation of Options and Issuance of Restricted Share Units

Retrieved on: 
Wednesday, July 21, 2021

WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.

Key Points: 
  • WINNIPEG, Manitoba, July 21, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the Company or Kane Biotech), today announces that it has cancelled 8,470,555 stock options of the Company (the Cancelled Options) of various directors, officers, employees and consultants of the Company.
  • The Company also wishes to announce the issuance of 10,739,488 restricted share units of the Company (RSUs) to various directors, officers, employees and consultants of the Company pursuant to the performance and restricted share unit plan of the Company dated April 21, 2021.
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Bio-Based Ethylene Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Raw Material and End-User Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021

The "Bio-Based Ethylene Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Raw Material and End-User Industry" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bio-Based Ethylene Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Raw Material and End-User Industry" report has been added to ResearchAndMarkets.com's offering.
  • Based on raw material, the global bio-based ethylene market is segmented into sugars, starch, and lignocellulosic biomass.
  • Sugar from sugarcane is a highly utilized raw material while producing bio ethylene, mainly in India and Brazil.
  • Thus, urgent need to reduce the dependency on fossil fuels and rise in awareness regarding environmental sustainability are bolstering the bio-based ethylene market growth.

Kane Biotech to meet investors at Whistler 2021 Capital Conference

Retrieved on: 
Tuesday, June 29, 2021

WINNIPEG, Manitoba, June 29, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. will host investor meetings at the 10th Annual Whistler 2021 Capital Conference hosted by Capital Event Management the weekend of July 9-11, 2021 at The Fairmont Chateau, Whistler.

Key Points: 
  • WINNIPEG, Manitoba, June 29, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. will host investor meetings at the 10th Annual Whistler 2021 Capital Conference hosted by Capital Event Management the weekend of July 9-11, 2021 at The Fairmont Chateau, Whistler.
  • For a company like Kane, the Whistler conference has provided valuable exposure to an active group of investors in an environment which allows for meaningful long-term relationships to develop with significant players in the capital markets, commented Edwards.
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Next Science Product Featured in Lifetime Channel Program on Treating Chronic Wounds

Retrieved on: 
Monday, June 28, 2021

Next Science (ASX:NXS), an innovative medical technology company and leader in treating biofilm-based infections in humans, today announced new educational broadcast content about chronic infections, which impact 17 million Americans each year.

Key Points: 
  • Next Science (ASX:NXS), an innovative medical technology company and leader in treating biofilm-based infections in humans, today announced new educational broadcast content about chronic infections, which impact 17 million Americans each year.
  • In the U.S., biofilm-related infections kill an estimated 550,000 people each year more than chronic lower respiratory diseases, diabetes and the flu/pneumonia combined.
  • Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center based in Jacksonville, Florida.
  • Tune in to The Balancing Act weekdays at 7:30 a.m. (ET/PT) on Lifetime, and find all previously aired episodes on TheBalancingAct.com.

Kane Biotech Announces Adoption of Performance and Restricted Share Unit Plan and Amended and Restated Stock Option Plan

Retrieved on: 
Wednesday, June 9, 2021

The PRSU Plan provides for the issuance of restricted share units and performance share units to employees, consultants, officers or directors of the Company and its subsidiaries.

Key Points: 
  • The PRSU Plan provides for the issuance of restricted share units and performance share units to employees, consultants, officers or directors of the Company and its subsidiaries.
  • The Amended and Restated SOP amends the prior stock option plan of the Company by removing the requirement that the maximum number of shares issuable under the Amended and Restated SOP include shares issuable pursuant to any other share-based plan grants or agreements of the Company (which would include the PRSU Plan).
  • Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Penn Dental Medicine Study Explores New Strategy for Avoiding Childhood Tooth Decay

Retrieved on: 
Monday, May 24, 2021

A few years ago, scientists from Penn Dental Medicine found that the dental plaque that gives rise to ECC is composed of both a bacterial species,Streptococcus mutans, and a fungus,Candida albicans.

Key Points: 
  • A few years ago, scientists from Penn Dental Medicine found that the dental plaque that gives rise to ECC is composed of both a bacterial species,Streptococcus mutans, and a fungus,Candida albicans.
  • The two form a sticky biofilm that becomes extremely difficult to displace from the tooth surface.
  • Now, a new study from the group offers a strategy for disrupting this biofilm by targeting the yeast-bacterial interactions.
  • "This offers us another tool for disrupting this virulent biofilm," says Geelsu Hwang , assistant professor at Penn Dental Medicine and senior author on the study, published in mBio .

Manganese X Subsidiary and JV Partner PureBiotic Air Inc. Provide Virginia State University Testing Update on Biofilm Deconstruction of Pathogens Including COVID-19

Retrieved on: 
Tuesday, May 18, 2021

We have now been notified that testing will resume on a regular basis with their staff as long as there are no additional COVID-19 interruptions.

Key Points: 
  • We have now been notified that testing will resume on a regular basis with their staff as long as there are no additional COVID-19 interruptions.
  • "\nThe initial VSU testing also included the successful production of the biofilm growth required to advance its research and testing of DBC\'s PureBiotic AIR HVAC Delivery System for the mitigation of infection risks, including COVID-19 and other contaminants.
  • Applications of the PureBiotic AIR Mist Solutions are currently being tested on the biofilm grown from specific pathogens selected from the common human environment.
  • Applications of PureBiotic AIR Mist Solutions should provide ongoing continuous protection long after the initial application.

Next Science’s XPERIENCE No Rinse Antimicrobial Solution Cleared by FDA for Sale in USA

Retrieved on: 
Tuesday, April 27, 2021

Established in 2012, the Company\xe2\x80\x99s primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health.

Key Points: 
  • Established in 2012, the Company\xe2\x80\x99s primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health.
  • Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria.
  • Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.
  • For further information visit: www.nextscience.com .\nThis announcement may contain forward looking statements which may be identified by words such as \xe2\x80\x9cbelieves\xe2\x80\x9d, \xe2\x80\x9cconsiders\xe2\x80\x9d, \xe2\x80\x9ccould\xe2\x80\x9d, \xe2\x80\x9cestimates\xe2\x80\x9d, \xe2\x80\x9cexpects\xe2\x80\x9d, \xe2\x80\x9cintends\xe2\x80\x9d, \xe2\x80\x9cmay\xe2\x80\x9d, and other similar words that involve risks and uncertainties.